Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gentamicin + piperacillin is a combination of two antibiotics used together for the treatment of serious bacterial infections, particularly those caused by Gram-negative and some Gram-positive organisms. Gentamicin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to cell death. Piperacillin is a broad-spectrum ureidopenicillin (beta-lactam) antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, resulting in bactericidal activity. The combination is often used synergistically in severe infections such as sepsis, endocarditis, and hospital-acquired pneumonia due to their complementary mechanisms and expanded antimicrobial coverage[3][8]. This regimen may be selected when resistance or mixed infections are suspected.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gentamicin + piperacillin.